Dutch study tracks COVID antivirals in High-Risk patients
NCT ID NCT05195060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed over 1,100 high-risk COVID-19 patients in the Netherlands who received new antiviral drugs or monoclonal antibodies. Researchers collected blood samples and nasal swabs over 90 days to see how the virus and the body's immune response changed during treatment. The goal was to learn which patients benefit most and to watch for new virus variants, not to test a new treatment directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam University Medical Centre
Amsterdam, North Holland, 1105 AZ, Netherlands
-
Amsterdam University Medical centre - VUMC
Amsterdam, North Holland, 1081 HV, Netherlands
-
Leiden universitair medisch centrum
Leiden, 2333ZA, Netherlands
-
Radboud Universitair Medisch Centrum
Nijmegen, 6525GA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?